[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_7126 

# __Use of experimental and unapproved drugs for covid-19 treatment__

## Articles mentionning the risk

* [Cirrincione_covid-19_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_441.md)

## Mitigations of this risk

* [Conduct rigorous clinical trials and research to assess the safety and efficacy of experimental drugs for covid-19 treatment](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_9007.md)

## Name of the risk

Potential risks of adverse reactions, drug ineffectiveness, and lack of standardized treatment protocols

## People affected by this risk

* [Covid-19 patients](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_68.md)
* [Healthcare workers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)
* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_501.md)

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_413.md)
* [Regulatory agencies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_401.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Clinical trial management systems](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_7998.md)
* [Drug safety monitoring technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_8679.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Failure to implement preventive measures](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_12.md)

